Dyslipidemia is associated with ventricular tachyarrhythmia in patients with acute ST-segment elevation myocardial
Yen-Bin Liu1, Chau-Chung Wu, Chii-Ming Lee
1Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University School of Medicine, Taipei, Taiwan, R.O.C.
Insights
Dyslipidemia, characterized by high LDL cholesterol, is linked to ventricular arrhythmias during acute myocardial infarction (MI). Managing lipid profiles may reduce sudden cardiac death risk post-MI.
Area of Science:
- Cardiology
- Internal Medicine
- Biochemistry
Background:
- Ventricular tachyarrhythmia is a major cause of sudden cardiac death in acute myocardial infarction (MI).
- Dyslipidemia is a common comorbidity in patients with cardiovascular disease.
- The association between dyslipidemia and ventricular tachycardia/fibrillation (VT/VF) in ST-segment elevation MI (STEMI) requires further investigation.
Purpose of the Study:
- To investigate the association between dyslipidemia and the occurrence of VT/VF during the acute phase of STEMI.
- To identify lipid profile parameters that predict VT/VF in acute MI patients.
Main Methods:
- A case-control study involving 58 patients with VT/VF (study group) and 58 matched patients without VT/VF (control group) after MI onset.
- Lipid profiles (TC, HDL-C, LDL-C, triglyceride) were measured within the first week and at 3 months post-MI.
- Multivariate analysis was used to identify independent predictors of VT/VF.
Main Results:
- Patients with VT/VF exhibited higher LDL-C levels during the acute stage and higher TC, LDL-C, and triglyceride levels at 3-month follow-up.
- Lower blood pressure on arrival was observed in the VT/VF group.
- Multivariate analysis identified 3-month LDL-C, admission blood pressure, and triglyceride level changes as independent predictors of VT/VF.
Conclusions:
- Dyslipidemia, particularly elevated LDL-C, is associated with an increased risk of ventricular tachyarrhythmia in the acute phase of STEMI.
- These findings highlight the importance of lipid management in preventing life-threatening arrhythmias after MI.
Background:
Ventricular tachyarrhythmia developing in the acute stage of myocardial infarction (MI) is an important cause of sudden cardiac death. The aim of this study was to determine whether dyslipidemia is associated with the occurrence of ventricular tachycardia/fibrillation (VT/VF) during the acute stage of ST-segment elevation MI (STEMI).
Methods:
A total of 58 patients experiencing VT/VF within 24 hours after the onset of MI were selected as the study group. A group of 58 patients with MI but without VT/VF was selected as the control group matched for sex (overall, 104 males), age (overall, 58 +/- 10 years), and the use of thrombolytic therapy (n = 82). The lipid profiles including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride were measured during the first week and at the third month after the index MI. Other coronary risk factors, and clinical, hemodynamic and angiographic characteristics were also included in the assessment.
Results:
During the acute stage, patients with VT/VF had higher levels of LDL-C and lower blood pressure on initial arrival at our hospital. At the 3-month follow-up, those patients with VT/VF showed higher levels of TC, LDL-C and triglyceride. Multivariate analysis revealed that LDL-C (p < 0.001) at the 3-month follow-up, mean blood pressure on arrival (p < 0.01), and the difference in triglyceride levels between the first week and the third month (p < 0.05) were independent predictors for the occurrence of VT/VF in the acute stage of MI.
Conclusion:
This study suggests that dyslipidemia imposes a higher risk of developing tachyarrhythmia in the acute phase of STEMI.
Related Concept Videos
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
01:14Myocarditis III: Medical Management
01:27Myocarditis II: Clinical Features and Diagnostic Tests